Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Erythropoietin Stories

2011-02-14 06:30:00

NES-ZIONA, Israel, Feb. 14, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today reported that patient enrollment and dosing in the Phase II trial of its long-acting version of human growth hormone (hGH-CTP) are proceeding according to plan, with study completion targeted for mid-year 2011. The study is assessing the efficacy of hGH-CTP by measuring IGF-1 levels in growth hormone deficient adults in...

2011-01-25 12:45:56

Evaluating patients for genetic variations impacts adherence to antiviral therapy In two recent studies, researchers have identified two functional variants in the inosine triphosphatase (ITPA) gene that protect patients with hepatitis C virus (HCV) against anemia brought on by antiviral treatment. The ability to identify those patients protected against treatment-induced anemia will ensure completion of antiviral therapy and successful elimination of the virus. Full findings of these studies...

2011-01-18 06:30:00

NES-ZIONA, Israel, Jan. 18, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation. The Reversible PEGylation technology has been shown in animal models to significantly enhance the half-life and improve the biological activity of a...

2010-12-30 13:04:56

Patients with diabetes, kidney disease and anemia who don't respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death, researchers at UT Southwestern Medical Center have found. The results suggest that testing such patients' responsiveness to the drug and keeping blood iron levels a little low might reduce their risk, said Dr. Robert Toto, professor of internal medicine and clinical sciences and a senior author of the study, which appeared in the New...

2010-12-09 11:19:00

HERZLIYA, Israel, December 9, 2010 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY.PK), a biopharmaceutical company, today announced it has been notified by the Tel Aviv Stock Exchange (TASE) that XTL will be included in the following TASE Indexes; "Yeter" Tel Aviv, "Tel Tech", and "Biomed", effective December 15, 2010. TASE shall conduct a "special trading" in XTL's shares at the end of trading on December 14, 2010. "We are very pleased that our...

2010-12-08 11:41:00

BANGALORE, India, December 8, 2010 /PRNewswire/ -- AVESTHAGEN LIMITED, a leading knowledge based life sciences company pioneering the convergence between Food, Pharma and Population Genetics, today announced the completion of manufacturing of the clinical grade material of its first biosimilar molecule- AVDESP(TM) (biosimilar to Darbepoetin alfa), which will now be moving into Clinical Trials. Inno Biologics, Malaysia's biopharma CMO has successfully developed Drug Substance batches for...

2010-12-06 03:25:00

PALO ALTO, Calif., Dec. 6, 2010 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced positive results from a Phase 2 multicenter trial of oral ezatiostat hydrochloride (TELINTRA, TLK199) in patients with an International Prognostic System Score (IPSS) of low to intermediate-1 risk myelodysplastic syndrome (MDS). The presentation entitled Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog,...

2010-12-02 15:18:00

THOUSAND OAKS, Calif., Dec. 2, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it will present data from several key Nplate® (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla. Results from six studies evaluating Nplate in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) add to the growing body of data supporting the use of...

2010-11-30 13:55:20

A drug called FG-2216 stimulates 'EPO' production -- even in patients without kidneys A new drug called FG-2216 can stimulate production of the hormone erythropoietin (EPO) in dialysis patients"”possibly offering a new approach to treatment of kidney disease-related anemia, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Anemia is a major problem in patients with kidney disease. It is caused by low production of EPO, which...

2010-11-30 07:52:25

(Ivanhoe Newswire) -- The name of the drug is FG-2216, and it's designed to stimulate production of the hormone erythropoietin (EPO) in dialysis patients.  In fact, it's the world's first oral drug for the treatment of kidney disease-related anemia; it's a hypoxia inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes the "master switch," which normally tells the body to produce EPO in response to low oxygen levels. Anemia, one of the more common blood disorders, is...